Innate Pharma reports H1 2026 cash €21.4M and net cash €0.1M
Innate Pharma says cash, cash equivalents, short-term investments and non-current financial assets were €21.4M at June 30, 2026, and net cash was €0.1M. It also reported declines in R&D and G&A expenses year-over-year.